Role of endocannabinoids on neuroinflammation in autism spectrum disorder prevention

Journal of Clinical and Diagnostic Research

Volumn 11, Issue 6, 2017, Pages CE01-CE03

  Habib, Syed Shahid ^a   Al Regaiey, Khalid ^a   Bashir, Shahid ^a   Iqbal, Muhammad ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Endocannabinoid system; Neuroimmunomodulation; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

AUTISM; BODY COMPOSITION; DISEASE SEVERITY; DOWN REGULATION; ENERGY BALANCE; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; MEMORY DISORDER; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SPASTICITY;

EID: 85020316574     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2017/23862.9969     Document Type: Review

References (33)

1. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcín C, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012;5(3):160-79.
2. Al-Salehi SM, Al-Hifthy EH, Ghaziuddin M. Autism in Saudi Arabia: presentation, clinical correlates and comorbidity. Transcult Psychiatry. 2009;46(2):340-47.
3. Ozonoff S, Iosif AM, Baguio F, Cook IC, Hill MM, Hutman T, et al. A prospective study of the emergence of early behavioral signs of autism. J Am Acad Child Adolesc Psychiatry. 2010;49(3):256-66.e1-2.
4. Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics. 2010;7(3):283-92.
5. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67-81.
6. Ziemssen T, Kern S. Psychoneuroimmunology–cross-talk between the immune and nervous systems. J Neurol. 2007;254:8–11.
7. Bessis A, Béchade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia. 2007;55(3):233-38.
8. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207(1-2):111-16.
9. Morgan JT, Barger N, Amaral DG, Schumann CM. Stereological study of amygdala glial populations in adolescents and adults with autism spectrum disorder. PLoS ONE. 2014;9(10):e110356.
10. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010;68(4):368-76.
11. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis. 2008;30:303–11.
12. Mead J, Ashwood P. Evidence supporting an altered immune response in ASD. Immunol Lett. 2015;163(1):49-55.
13. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm. 2015;2015:531518.
14. Careaga M, Ashwood P. Autism spectrum disorders: from immunity to behavior. Methods Mol Biol. 2012;934:219-40.
15. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res. 2007;56:382–92.
16. Drysdale AJ, Platt B. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem. 2003;10(24):2719-32.
17. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci. 2005;23(2-3):183-87.
18. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, et al. Mapping early brain development in autism. Neuron. 2007;56(2):399-413.
19. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol. 2004;5:575–81.
20. Killestein J, Hoogervorst EL, Reif M, Blauw B, Smits M, Uitdehaag BM, et al. Immunomodulatory effects of orally dministered cannabinoids in multiple sclerosis. J Neuroimmunol. 2003;137(1-2):140-43.
21. Maestroni GJ. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J. 2004;18(15):1914-16.
22. Wong ML, Sternberg EM. Immunological assays for understanding neuroimmune interactions. Arch Neurol. 2000;57:948–52.
23. Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology. 2010;215(8):606-10.
24. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M.The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007;28(4):180-87.
25. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord. 2013;43:2686–95.
26. Campolongo P, Trezza V, Palmery M, Trabace L, Cuomo V. Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol. 2009;85:117-33.
27. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008;1(2):114-23.
28. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-49.
29. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25(8):1904-13.
30. Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006;63(12):1410-24.
31. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003;23(7):2511-16.
32. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006;49(1):67-79.
33. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280(36):31405-12.